Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | FAM20C | Q8IXL6 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.53 |
| ▸ | PRKCB | P05771 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKCH | P24723 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575060 | 0.92 | IGF1R (0.58) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL1131571 | 0.89 | IGF1R (0.55) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL1575537 | 0.87 | IGF1R (0.63) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL1222128 | 0.84 | IGF1R (0.63) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL1130949 | 0.84 | AURKA (0.51) | IGF1REGFRCDK2AURKACDC7 | |
| SCHEMBL1131002 | 0.84 | LYN (0.54) | EGFRCDK2AURKALCKCDC7 | |
| SCHEMBL13015141 | 0.83 | IGF1R (0.51) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL1131616 | 0.83 | AURKA (0.49) | IGF1REGFRCDK2AURKACDC7 | |
| SCHEMBL14898950 | 0.82 | IGF1R (0.64) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL1131678 | 0.82 | IGF1R (0.55) | IGF1REGFRCDK2KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130345180-A1 | 2,4- DIAMINOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-12-26 | — | — | US | disclosed |
| US-8431589-B2 | 2,4-diaminopyrimidine derivatives | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-8431589-B2 | 2,4-diaminopyrimidine derivatives | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| EP-2308855-B1 | 2,4-Diaminopyrimidine derivatives | NOVARTIS AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| EP-1487805-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| EP-1487805-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20110172231-A1 | 2,4- DIAMINOPYRIMIDINE DERIVATIVES | NOVARTIS AG | 2011-07-14 | — | — | US | disclosed |
| US-7943627-B2 | 2,4-diaminopyrimidine derivatives | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7943627-B2 | 2,4-diaminopyrimidine derivatives | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7943627-B2 | 2,4-diaminopyrimidine derivatives | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| EP-2308855-A1 | 2,4-Diaminopyrimidine derivatives | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308855-A1 | 2,4-Diaminopyrimidine derivatives | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20070105839-A1 | 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders | IMBACH PATRICIA | 2007-05-10 | — | — | US | disclosed |
| US-20070105839-A1 | 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders | IMBACH PATRICIA | 2007-05-10 | — | — | US | disclosed |
| US-20070105839-A1 | 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders | IMBACH PATRICIA | 2007-05-10 | — | — | US | disclosed |
| US-20060100227-A1 | Pyrimidine derivaties | NOVARTIS AG (CH) | 2006-05-11 | — | — | US | disclosed |
| EP-1487805-A1 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078404-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172231-A1 | 2,4- DIAMINOPYRIMIDINE DERIVATIVES | ZAP70, SYK, BTK | IGF1R 705/4885EGFR 629/4885INSR 1441/4885 |
| US-20070105839-A1 | 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders | TYMP, DPYD, DERA | IGF1R 2614/4885EGFR 744/4885INSR 2793/4885 |
| US-20060100227-A1 | Pyrimidine derivaties | ZAP70, SYK, BTK | IGF1R 577/4885EGFR 1269/4885INSR 1451/4885 |
| US-20130345180-A1 | 2,4- DIAMINOPYRIMIDINE DERIVATIVES | ZAP70, SYK, BTK | IGF1R 705/4885EGFR 629/4885INSR 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.